POWERFUL NEWS:

MMRF PRESS RELEASES


Multiple Myeloma Research Consortium to Present Data in Eight Oral or Poster Sessions at 53rd American Society of Hematology (ASH) Annual Meeting


High-impact Data on Improving Clinical Trial Enrollment and Acceleration

Norwalk, CT — December 6, 2011

The Multiple Myeloma Research Consortium (MMRC) today announced that eight abstracts from its clinical collaborations with academia and industry have been accepted for oral and poster presentations at this year's American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2011 in San Diego, California.

In an oral presentation, the MMRC will unveil important data related to improvements in research and development timelines for multiple myeloma studies conducted within the Consortium. Among the data to be presented will be key metrics related to accelerated trial start-up and patient accrual times, which ultimately result in rapid access to novel compounds for patients and physicians.

The other seven presentations encompass results from myeloma trials conducted with MMRC support and project management resources and represent studies across the most promising areas of myeloma research and development. Among these MMRC presentations will be data on potential treatments for relapsed/refractory multiple myeloma, including Phase 1 results of a novel proteasome inhibitor, marizomib; Phase 2 results of elotuzumab in combination with lenalidomide and low-dose dexamethasone; and final results for the bortezomib-naïve group in a Phase 2 study of single-agent carfilzomib. Also being presented are results of a retrospective subset analysis of elotuzumab combined with lenalidomide and low-dose dexamethasone in high risk and/or stage 2-3 relapsed/refractory multiple myeloma, and results from a study on cytogenetic characteristics and response rates for relapsed/refractory patients treated with carfilzomib. In addition, an update from the Vantage Study Program Phase 2b study evaluating vorinostat in combination with bortezomib as a salvage therapy in double refractory patients (bortezomib and IMiDs) will be presented, as well as final results of a Phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone.

“These data collectively demonstrate the important work the MMRC is supporting with our unique research model to drive innovation in multiple myeloma treatment and provide new treatment options to patients as quickly as possible,” said Walter Capone, Chief Operating Officer, Multiple Myeloma Research Foundation (MMRF). “We are encouraged by the results across these studies, and are incredibly proud of the collaborative work our research and industry partners are doing to address the need for breakthrough treatments for this currently incurable disease.”

MMRC presentations at ASH will include:

Abstract #: 302
TITLE: Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
MMRC Trial Lead Author: Paul G. Richardson, MD
Oral Session: 653. Myeloma – Therapy, excluding Transplantation: New Agents in Myeloma
Date: Monday, December 12, 2011
Presentation Time: 7:15 AM
Location: Ballroom 20D (San Diego Convention Center)

 

Abstract #: 303
TITLE: A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
MMRC Trial Lead Author: Sagar Lonial, MD
Oral Session: 653. Myeloma – Therapy, excluding Transplantation: New Agents in Myeloma
Date: Monday, December 12, 2011
Presentation Time: 7:30 AM
Location: Ballroom 20D (San Diego Convention Center)

 

Abstract #: 480
TITLE: Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial
MMRC Trial Lead Author: David S. Siegel, MD, PhD
Oral Session: 653. Myeloma – Therapy, excluding Transplantation I
Date: Monday, December 12, 2011
Presentation Time: 11:45 AM
Location: Ballroom 20D (San Diego Convention Center)

 

Abstract #: 631
TITLE: Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)
MMRC Trial Lead Author: Andrzej J Jakubowiak, MD, PhD
Oral Session: 653. Myeloma – Therapy, excluding Transplantation: Combinations Therapy for Myeloma
Date: Monday, December 12, 2011
Presentation Time: 2:45 PM
Location: Ballroom 20D (San Diego Convention Center)

 

Abstract #: 813
TITLE: Final Results from the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
MMRC Trial Lead Author: Ravi Vij, MD
Oral Session: 653. Myeloma – Therapy, excluding Transplantation: Novel drugs in relapsed/refractory myeloma patients
Date: Monday, December 12, 2011
Presentation Time: 5:00 PM
Location: Ballroom 20D (San Diego Convention Center)

 

Abstract #: 1024
TITLE: The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up And Accrual Metrics Speeds Drug Development
MMRC Trial Lead Author: Sandra M. Wear, RN
Oral Session: 901. Health Services and Outcome Research: Getting Patients the Care They Need – Personalization and Quality of Care for Patients with Malignancies
Date: Tuesday, December 13, 2011
Presentation Time: 8:15 AM
Location: Elizabeth Ballroom FG (Manchester Grand Hyatt San Diego)

 

Abstract #: 1875
TITLE: Unfavorable Cytogenetic Characteristics Do No Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study
MMRC Trial Lead Author: Andrzej J Jakubowiak, MD, PhD
Poster Session: 653. Myeloma – Therapy, excluding Transplantation: Poster I
Date: Saturday, December 10, 2011
Presentation Time: 5:30-7:30 PM
Location: Hall GH (San Diego Convention Center)

 

Abstract #: 3968
TITLE: Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study
MMRC Trial Lead Author: Sundar Jagannath, MD
Poster Session: 653. Myeloma – Therapy, excluding Transplantation: Poster III
Date: Monday, December 12, 2011
Presentation Time: 6:00-8:00 PM
Location: Hall GH (San Diego Convention Center)

 

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)
Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $170 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated more than 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donors' investments, the MMRF has been consistently recognized for its sound fiscal management. For more information about the MMRF, please visit www.themmrf.org.

About the Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, Washington University in St. Louis, and Barbara Ann Karmanos Cancer Institute.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas in genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.

Media Contacts:

Eileen Regan, MMRF
203-652-0232
ReganE@themmrf.org

Cara Amoroso, Feinstein Kean Healthcare
202-729-4013
Cara.Amoroso@fkhealth.com